LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 399

Search options

  1. Article: Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True?

    Siedner, Mark J

    Open forum infectious diseases

    2021  Volume 8, Issue 11, Page(s) ofab318

    Language English
    Publishing date 2021-06-14
    Publishing country United States
    Document type Editorial
    ZDB-ID 2757767-3
    ISSN 2328-8957
    ISSN 2328-8957
    DOI 10.1093/ofid/ofab318
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Is it time to make 'undetectable for all' the global standard for HIV care?

    McCluskey, Suzanne M / Siedner, Mark J

    AIDS (London, England)

    2023  Volume 37, Issue 9, Page(s) 1471–1472

    MeSH term(s) Humans ; HIV Infections/drug therapy ; World Health Organization
    Language English
    Publishing date 2023-07-03
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 639076-6
    ISSN 1473-5571 ; 0269-9370 ; 1350-2840
    ISSN (online) 1473-5571
    ISSN 0269-9370 ; 1350-2840
    DOI 10.1097/QAD.0000000000003605
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Pre-Existing Population Immunity and severe acute respiratory syndrome coronavirus 2 Variant Establishment and Dominance Dynamics in the United States: An Ecological Study.

    Ankomah, Pierre O / Siedner, Mark J / Bhattacharyya, Roby P

    Open forum infectious diseases

    2022  Volume 9, Issue 12, Page(s) ofac621

    Abstract: We conducted an ecological analysis of the dynamics of Delta and Omicron establishment and dominance in US states. Omicron became the dominant circulating variant later in states with higher population-level immunity. By contrast, population immunity did ...

    Abstract We conducted an ecological analysis of the dynamics of Delta and Omicron establishment and dominance in US states. Omicron became the dominant circulating variant later in states with higher population-level immunity. By contrast, population immunity did not impact the maximum rate of takeover by Delta or Omicron from prior variants.
    Language English
    Publishing date 2022-12-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2757767-3
    ISSN 2328-8957
    ISSN 2328-8957
    DOI 10.1093/ofid/ofac621
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Aging, Health, and Quality of Life for Older People Living With HIV in Sub-Saharan Africa: A Review and Proposed Conceptual Framework.

    Siedner, Mark J

    Journal of aging and health

    2017  Volume 31, Issue 1, Page(s) 109–138

    Abstract: Objective: The number of people living with HIV (PLWH) over 50 years old in sub-Saharan Africa is predicted to triple in the coming decades, to 6-10 million. Yet, there is a paucity of data on the determinants of health and quality of life for older ... ...

    Abstract Objective: The number of people living with HIV (PLWH) over 50 years old in sub-Saharan Africa is predicted to triple in the coming decades, to 6-10 million. Yet, there is a paucity of data on the determinants of health and quality of life for older PLWH in the region.
    Methods: A review was undertaken to describe the impact of HIV infection on aging for PLWH in sub-Saharan Africa.
    Results: We (a) summarize the pathophysiology and epidemiology of aging with HIV in resource-rich settings, and (b) describe how these relationships might differ in sub-Saharan Africa, (c) propose a conceptual framework to describe determinants of quality of life for older PLWH, and (d) suggest priority research areas needed to ensure long-term gains in quality of life for PLWH in the region.
    Conclusions: Differences in traditional, lifestyle, and envirnomental risk factors, as well as unique features of HIV epidemiology and care delivery appear to substantially alter the contribution of HIV to aging in sub-Saharan Africa. Meanwhile, unique preferences and conceptualizations of quality of life will require novel measurement and intervention tools. An expanded research and public health infrastructure is needed to ensure that gains made in HIV prevention and treamtent are translated into long-term benefits in this region.
    MeSH term(s) Africa South of the Sahara/epidemiology ; Aged ; Aging/physiology ; Aging/psychology ; Delivery of Health Care ; Epidemiologic Factors ; Female ; Geriatric Assessment ; HIV Infections/epidemiology ; Health Services Needs and Demand ; Health Status Disparities ; Humans ; Male ; Middle Aged ; Quality of Life ; Risk Factors
    Language English
    Publishing date 2017-08-23
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 1045392-1
    ISSN 1552-6887 ; 0898-2643
    ISSN (online) 1552-6887
    ISSN 0898-2643
    DOI 10.1177/0898264317724549
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Proposing Minimum Requirements for Announcing Clinical Trial Results During the COVID-19 Pandemic.

    Siedner, Mark J / Gandhi, Rajesh T

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2020  Volume 72, Issue 7, Page(s) 1265–1267

    Abstract: Recently, results from at least six major randomized clinical trials studying management of COVID-19 have been announced via press release. Given the unique nature of the pandemic, results of such trials often have immediate and worldwide relevance. Yet, ...

    Abstract Recently, results from at least six major randomized clinical trials studying management of COVID-19 have been announced via press release. Given the unique nature of the pandemic, results of such trials often have immediate and worldwide relevance. Yet, while press releases serve the important purpose of disseminating top-level results quickly, they are inherently limited in scope, and rarely include sufficient data to inform practice. Herein, we propose a minimum set of trial characteristics and results to be released simultaneously with clinical trial announcements. This practice will ensure data related to the management of COVID-19 can be used to appropriately impact care, while responding to the needs of diverse stakeholders in the scientific and publishing communities, as well as the public at large.
    MeSH term(s) COVID-19 ; Humans ; Pandemics/prevention & control ; Publishing ; Randomized Controlled Trials as Topic ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-07-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciaa945
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection.

    Siedner, Mark J

    Open forum infectious diseases

    2016  Volume 3, Issue 1, Page(s) ofw032

    Abstract: The Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection (START) study has reinforced the benefits of early initiation of antiretroviral therapy (ART). However, a notable secondary finding from that study was that immediate initiation ...

    Abstract The Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection (START) study has reinforced the benefits of early initiation of antiretroviral therapy (ART). However, a notable secondary finding from that study was that immediate initiation of ART did not prevent cardiovascular disease (CVD) events (0.17 vs 0.20 events/1000 person-years, P = .65). This result appears to contradict a body of evidence, most notably from the Strategies for Management of Antiretroviral Therapy (SMART) study, which reported a 70% increased hazard of cardiovascular events for those deferring or interrupting treatment. Thus, an important unresolved question is whether the timing of ART impacts CVD risk. In this review, published data on relationships between timing of ART and CVD risk are reviewed. The data support a role for ART in mitigating CVD risk at lower CD4 counts, but data also suggests that, among those initiating therapy early, ART alone appears to suboptimally mitigate CVD risk. Additional interventions to address CVD risk among human immunodeficiency virus-infected populations are likely to be needed.
    Language English
    Publishing date 2016-02-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2757767-3
    ISSN 2328-8957
    ISSN 2328-8957
    DOI 10.1093/ofid/ofw032
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Weight gain and aging in people with HIV.

    Taramasso, Lucia / Stapleton, Jack T / Siedner, Mark J

    AIDS (London, England)

    2021  Volume 35, Issue 6, Page(s) 987–989

    MeSH term(s) Aged ; Aging ; HIV Infections ; Heterocyclic Compounds, 3-Ring ; Humans ; Oxazines ; Piperazines ; Pyridones ; Weight Gain
    Chemical Substances Heterocyclic Compounds, 3-Ring ; Oxazines ; Piperazines ; Pyridones ; dolutegravir (DKO1W9H7M1)
    Language English
    Publishing date 2021-04-05
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 639076-6
    ISSN 1473-5571 ; 0269-9370 ; 1350-2840
    ISSN (online) 1473-5571
    ISSN 0269-9370 ; 1350-2840
    DOI 10.1097/QAD.0000000000002849
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Roadmap for Achieving Universal Antiretroviral Treatment.

    Sokhela, Simiso / Lalla-Edward, Samanta / Siedner, Mark J / Majam, Mohammed / Venter, Willem Daniel Francois

    Annual review of pharmacology and toxicology

    2023  Volume 63, Page(s) 99–117

    Abstract: Modern antiretroviral therapy safely, potently, and durably suppresses human immunodeficiency virus (HIV) that, if left untreated, predictably causes acquired immunodeficiency syndrome (AIDS), which has been responsible for tens of millions of deaths ... ...

    Abstract Modern antiretroviral therapy safely, potently, and durably suppresses human immunodeficiency virus (HIV) that, if left untreated, predictably causes acquired immunodeficiency syndrome (AIDS), which has been responsible for tens of millions of deaths globally since it was described in 1981. In one of the most extraordinary medical success stories in modern times, a combination of pioneering basic science, innovative drug development, and ambitious public health programming resulted in access to lifesaving, safe drugs, taken as an oral tablet daily, for most of the world. However, substantial challenges remain in the fields of prevention, timely access to diagnosis, and treatment, especially in pediatric and adolescent patients. As HIV-positive adults age, treating their comorbidities will require understanding the course of different chronic diseases complicated by HIV-related and antiretroviral toxicities and finding potential treatments. Finally, new long-acting antiretrovirals on the horizon promise exciting new options in both the prevention and treatment fields.
    MeSH term(s) Adult ; Adolescent ; Humans ; Child ; Anti-HIV Agents/pharmacology ; Anti-HIV Agents/therapeutic use ; HIV Infections/drug therapy ; Acquired Immunodeficiency Syndrome/drug therapy
    Chemical Substances Anti-HIV Agents
    Language English
    Publishing date 2023-01-23
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 196587-6
    ISSN 1545-4304 ; 0362-1642
    ISSN (online) 1545-4304
    ISSN 0362-1642
    DOI 10.1146/annurev-pharmtox-052020-094321
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Circulating resistance to first-line HIV drug regimens.

    Iwuji, Collins C / Siedner, Mark J

    The lancet. HIV

    2019  Volume 7, Issue 2, Page(s) e77–e78

    MeSH term(s) Anti-HIV Agents/therapeutic use ; Drug Resistance, Viral/genetics ; HIV Infections/drug therapy ; HIV Infections/virology ; HIV Integrase Inhibitors/therapeutic use ; Humans ; Practice Guidelines as Topic ; Reverse Transcriptase Inhibitors/therapeutic use ; Treatment Outcome ; Viral Load/drug effects
    Chemical Substances Anti-HIV Agents ; HIV Integrase Inhibitors ; Reverse Transcriptase Inhibitors
    Language English
    Publishing date 2019-12-07
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2352-3018
    ISSN (online) 2352-3018
    DOI 10.1016/S2352-3018(19)30374-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care.

    Triant, Virginia A / Siedner, Mark J

    The Journal of infectious diseases

    2019  Volume 221, Issue 4, Page(s) 498–500

    MeSH term(s) Atazanavir Sulfate ; Cardiovascular Diseases ; Case-Control Studies ; Darunavir ; HIV ; HIV Infections ; HIV Protease Inhibitors ; Humans ; Myocardial Infarction ; Risk Factors
    Chemical Substances HIV Protease Inhibitors ; Atazanavir Sulfate (4MT4VIE29P) ; Darunavir (YO603Y8113)
    Language English
    Publishing date 2019-12-10
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1093/infdis/jiz482
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top